At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Floxuridine, and 5 other interventions for Esophageal Cancer. Completed, enrolled 29 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, floxuridine, docetaxel, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with previously untreated stage II or stage III esophageal cancer that can be removed by surgery.
Study Details
Timeline
Interventions
Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Intravenously, 85 mg/m2, over 2 hours, 2 cycles
Analysis of tumor for pathologic response to protocol therapy
Analysis of tumor for pathologic response to protocol therapy
Surgical removal of tumor for correlative studies